<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00701883</url>
  </required_header>
  <id_info>
    <org_study_id>70,961</org_study_id>
    <secondary_id>M8025-20711</secondary_id>
    <nct_id>NCT00701883</nct_id>
  </id_info>
  <brief_title>Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Moderately Overweight Patients With High Cholesterol</brief_title>
  <acronym>MBX-8025</acronym>
  <official_title>Multicenter Randomized Double-Blind Placebo and Active Comparator Controlled Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of MBX-8025 in Moderately Obese Hyperlipidemic Patients With/Out Concomitant Atorvastatin&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CymaBay Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CymaBay Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multicenter Randomized, Double-Blind, Placebo-Controlled Study to evaluate the efficacy,
      safety and tolerability of MBX-8025, a novel PPAR-d agonist to treat hyperlipidemia, insulin
      resistance and obesity in overweight, hyperlipidemic patients, both as monotherapy and in
      combination with Atorvastatin

      Total participation for each patient is approximately 16-17 weeks, which may include up to a
      2 week screening period, 5 week run-in period, 8 week treatment period, and 2 week follow-up.
      During the run-in period patients taking statins, statin combination or Zetia will undergo a
      'washout'. All patients will be instructed to follow a weight-maintenance diet (i.e., their
      same diet prior to entering the study). They will be asked to defer initiating any weight
      loss diets or meaningful changes in their activity level until after they have completed the
      study. Once randomized into the double blind study, patients will visit the clinic every two
      weeks thereafter until the end of the study. At the end of the 8-week treatment phase, the
      double-blind study medication will be discontinued. Patients will attend a follow up visit
      two weeks after their final dose for safety evaluation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Total participation for each patient is approximately 16-17 weeks, which may include up to a
      2 week screening period, 5 week run-in period, 8 week treatment period, and 2 week follow-up.
      During the run-in period patients taking statins, statin combination or Zetia will undergo a
      'washout'. All patients will be instructed to follow a weight-maintenance diet (i.e., their
      same diet prior to entering the study). They will be asked to defer initiating any weight
      loss diets or meaningful changes in their activity level until after they have completed the
      study. Once randomized into the double blind study, patients will visit the clinic every two
      weeks thereafter until the end of the study. At the end of the 8-week treatment phase, the
      double-blind study medication will be discontinued. Patients will attend a follow up visit
      two weeks after their final dose for safety evaluation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lipid levels will be measured in patients with hyperlipidemia to assess the benefits of the investigational drug</measure>
    <time_frame>8 week treatment period</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">183</enrollment>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Placebo/Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MBX-8025 50 mg/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MBX-8025 100 mg/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/Atorvastatin 20 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MBX-8025 50 mg/Atorvastatin 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MBX-8025 100 mg/Atorvastatin 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 capsules, once a day for 8 weeks</description>
    <arm_group_label>Placebo/Placebo</arm_group_label>
    <arm_group_label>MBX-8025 50 mg/Placebo</arm_group_label>
    <arm_group_label>MBX-8025 100 mg/Placebo</arm_group_label>
    <arm_group_label>Placebo/Atorvastatin 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MBX-8025</intervention_name>
    <description>2 capsules, once daily for 8 weeks</description>
    <arm_group_label>MBX-8025 50 mg/Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MBX-8025</intervention_name>
    <description>2 capsule, once daily for 8 weeks</description>
    <arm_group_label>MBX-8025 100 mg/Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>2 capsules, once daily for 8 weeks</description>
    <arm_group_label>Placebo/Atorvastatin 20 mg</arm_group_label>
    <arm_group_label>MBX-8025 50 mg/Atorvastatin 20 mg</arm_group_label>
    <arm_group_label>MBX-8025 100 mg/Atorvastatin 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MBX-8025</intervention_name>
    <description>2 capsules, once daily for 8 weeks</description>
    <arm_group_label>MBX-8025 50 mg/Atorvastatin 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MBX-8025</intervention_name>
    <description>2 capsules, once daily for 8 weeks</description>
    <arm_group_label>MBX-8025 100 mg/Atorvastatin 20 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18-75 years

          -  Female patients must not be pregnant or breast-feeding

          -  Patients must be moderately overweight

          -  All patients must have abnormal cholesterol levels or a history of abnormal
             cholesterol levels as defined by the protocol.

          -  Patients taking medication to lower their cholesterol must be willing, in some cases,
             to discontinue their medications during the study Stable weight (a history of
             increasing or decreasing no more than 6.6 lbs [3 kg]) for at least 2 months prior to
             the study;

        Exclusion Criteria

          -  Cancer or a history of a cancer within 5 years before screening, other than some skin
             cancers

          -  Patients planning elective surgery during the study

          -  Patients with a history of diabetes mellitus at study onset

          -  History of intolerance to, or adverse effect from atorvastatin

          -  History of weight loss due to stomach bypass or eating disorder

          -  All patients may not have had a stroke, TIA, an acute myocardial infarction, angina
             pectoris, coronary intervention procedure (including but not limited to angioplasty,
             stent placement, coronary revascularization) lower extremity bypass procedure,
             systemic or intracoronary fibrinolytic therapy) within 5 months of screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Roberts, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>CymaBay Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anasazi Internal Medicine Research</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes/Lipid Management and Research Center</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Consulting LLC</name>
      <address>
        <city>Milford</city>
        <state>Connecticut</state>
        <zip>06460</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genesis Research International</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Institute for Clinical Research Inc.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L-Marc Research Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Research Associates</name>
      <address>
        <city>Auburn</city>
        <state>Maine</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Trends Research LLC</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Troy Internal Medicine Research</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bridgewater Medical Group</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clifton-Wallington Medical Group</name>
      <address>
        <city>Clifton</city>
        <state>New Jersey</state>
        <zip>07013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Clinical Research</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United Medical Associates P.C.</name>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <zip>13901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Clinical Research</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southgate Medical Group</name>
      <address>
        <city>West Seneca</city>
        <state>New York</state>
        <zip>14224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Lakes Medical Research</name>
      <address>
        <city>Westfield</city>
        <state>New York</state>
        <zip>14787</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PharmQuest</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crescent Medical Research</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Medical Research Associates</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PHA-Adult Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tricities Medical Research</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holston Medical Group Clinical Research</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dallas Diabetes and Endocrine Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes and Glandular Disease Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walla Walla Clinic</name>
      <address>
        <city>Walla Walla</city>
        <state>Washington</state>
        <zip>99362</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2008</study_first_submitted>
  <study_first_submitted_qc>June 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2008</study_first_posted>
  <disposition_first_submitted>February 16, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>April 29, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 18, 2015</disposition_first_posted>
  <last_update_submitted>May 19, 2015</last_update_submitted>
  <last_update_submitted_qc>May 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cholesterol</keyword>
  <keyword>Hyperlipidemia</keyword>
  <keyword>HDL</keyword>
  <keyword>LDL</keyword>
  <keyword>Triglycerides</keyword>
  <keyword>Dyslipidemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

